Summary Although medulloblastoma and neuroblastoma share many common biological, histological and immunological features, the frequency of N-myc amplification differs markedly between the two tumours. In this study, Southern blot analysis revealed that the N-myc gene was not amplified in any of the nine medulloblastoma samples analysed. In contrast, over-expression of the gene was found in six of 11 (Garson et al., 1985) and increased expression reported in both fetal brain (Grady et al., 1987) and retinoblastoma (Lee et al., 1984) . Certain nonneuroectoderm derived tumours such as embryonal rhabdomyosarcoma have also been shown to carry amplified sequences of N-myc Mitani et al., 1986) . In addition, specimens of Wilm's tumours and teratomas have been shown to overexpress the N-myc gene (Nisen et al., 1986; Jakobovits et al., 1985). These observations, along with the finding that only some 38% of stage III and IV tumours show N-myc amplification, have reduced the diagnostic significance of this molecular abnormality (Brodeur et al., 1988) . However, information regarding the N-myc status of neuroblastoma has been shown to be of prognostic importance. Of particular relevance is the observation that patients with Evans stage II disease, that carry the amplification, have a poorer outcome than those with a single copy of the N-myc gene per haploid genome (Seeger et al., 1985 Medulloblastoma is a tumour of neuroectoderm origin, with some biochemical and immunological features in common with neuroblastoma (Rorke et al., 1986) . Only occasional, single case reports of N-myc expression in this malignancy have been published previously (Nisen et al., 1986) . In addition, c-myc amplification has been observed in the medulloblastoma-derived cell line D341 (Friedman et al., 1988). In this paper we detail studies on N-myc amplification and expression in 12 medulloblastoma biopsies. Controls using cell lines expressing either the N-myc and/or c-myc proteins have revealed approximately 50% of the samples analysed overexpress the N-myc gene.
Following the original report of N-myc amplification in neuroblastoma, other neuroectoderm derived tumours have been shown either to carry the amplification or to overexpress the gene. Amplification has been noted in a case of a paediatric astrocytoma (Garson et al., 1985) and increased expression reported in both fetal brain (Grady et al., 1987) and retinoblastoma (Lee et al., 1984) . Certain nonneuroectoderm derived tumours such as embryonal rhabdomyosarcoma have also been shown to carry amplified sequences of N-myc Mitani et al., 1986) . In addition, specimens of Wilm's tumours and teratomas have been shown to overexpress the N-myc gene (Nisen et al., 1986; Jakobovits et al., 1985) . These observations, along with the finding that only some 38% of stage III and IV tumours show N-myc amplification, have reduced the diagnostic significance of this molecular abnormality (Brodeur et al., 1988) . However, information regarding the N-myc status of neuroblastoma has been shown to be of prognostic importance. Of particular relevance is the observation that patients with Evans stage II disease, that carry the amplification, have a poorer outcome than those with a single copy of the N-myc gene per haploid genome (Seeger et al., 1985) . Further information concerning the diagnostic and prognostic importance of N-myc would become available if overexpression of the gene was also investigated. Unfortunately, many tumour biopsies do not lend themselves to this type of analysis due to the labile nature of RNA.
Within the past two or three years, immunological approaches to studying the c-myc and N-myc proteins have become available. Ikegaki et al. (1986) used monoclonal antibodies raised against a bacterially expressed lac z fusion protein containing a portion of the N-myc sequence to detect nuclear staining in the neuroblastoma cell line IMR5. Similarly, Slamon et al. (1986) raised a rabbit antiserum against a bovine growth hormone/N-myc fusion protein and reported nuclear staining in cell lines and biopsy samples from tumours known to amplify and overexpress the N-myc gene. Using an alternative approach, Ramsay et al. (1986) described an antiserum raised against a synthetic peptide representative of a sequence present in the N-myc gene. This biochemical procedures, but not to bond to the nuclear protein in immunocytochemical studies.
Medulloblastoma is a tumour of neuroectoderm origin, with some biochemical and immunological features in common with neuroblastoma (Rorke et al., 1986) . Only occasional, single case reports of N-myc expression in this malignancy have been published previously (Nisen et al., 1986) . In addition, c-myc amplification has been observed in the medulloblastoma-derived cell line D341 (Friedman et al., 1988) . In this paper we detail studies on N-myc amplification and expression in 12 medulloblastoma biopsies. Controls using cell lines expressing either the N-myc and/or c-myc proteins have revealed approximately 50% of the samples analysed overexpress the N-myc gene.
Materials and methods
Tissues and sections Tissues taken at operation were immediately cut into 2-3 mm blocks, placed into freezing vials and dropped into liquid nitrogen. Cryostat sections (5-6 ,um) were placed on to gelatine coated slides and stained with antisera to the N-myc gene product as described below. In addition, Haematoxylin and Eosin sections were prepared to ensure that tissues used for Southern and Western blot analysis consisted of viable tumour. Histological confirmation of the diagnosis was provided by the Department of Neuropathology, Frenchay Hospital, Bristol, United Kingdom.
Cell lines
The human neuroblastoma cell line was a gift from Dr P. Rabbitts, Ludwig Institute, Cambridge, UK, and the medulloblastoma cell line T671 was a gift from Dr Zeltser, UCLA, Los Angeles, USA. These lines, along with the colorectal carcinoma line, COLO 320.DM, were grown at 37°C in a 6% CO2 adherent cultures using RPMI 1640 supplemented with 10% fetal calf serum 100IUml-1 of penicillin and 100pgml-1 of streptomycin.
The T-cell leukaemic line GH1 and the promyelocytic leukaemic line HL60 were grown as suspension cultures in the medium described above. All cell lines were harvested in exponential growth phase for studies in N-myc and c-myc expression. The Kelly (YK) cell lines carries 100-fold amplification of the N-myc gene and overexpresses N-myc RNA (Shwab et al., 1983) . The HL 60 and COLO 320.DM cells over-express the c-myc gene product (Boultwood et al., 1988; Erisman et al., 1988) . The T-cell line GHl does not express either c-myc or N-myc as determined by Northern blot analysis (unpublished observation).
Southern blot analysis DNA was prepared from tissues and cell lines using standard techniques (Mantiatis et al., 1982) . This was digested with EcoRI and fragments separated by agarose gel electrophoresis. DNA was transferred to gene screen solid support and this was incubated with the N-myc probe pNb-I labelled with 32P by the oligo-labelling technique of Feinberg & Vogelstein (1983) . After washing the blots at high stringency, autoradiographs were exposed for 48 h on preflashed Kodak XAR-5 film with an intensifier screen. The N-myc gene copy number was estimated relative to placental DNA single copy intensity and molecular weights were calculated from lambda Hind III restriction fragment standards.
Antiserum to the N-myc protein Antisera were raised to: (1) a synthetic peptide representing an amino acid sequence unique to the N-myc gene product (reference: OA-1 1-803); (2) a synthetic peptide representing an amino acid sequence largely conversed in the N-myc, cmyc and L-myc oncoproteins (reference: OA-1 1-80 1).
The sequences are identified and their relative positions in exons 2 and 3 from c-myc, N-myc and L-myc are given in Figure 1 . OA-11-803 was affinity purified against the N-myc peptide.
Immunocytochemical staining
Cryostat sections (6 pm) or cytospin preparations on gelatine coated slides were fixed for 5min in 3.7% formaldehyde/ phosphate buffered saline (PBS). Slides were treated with 2.5% Triton X-100 in PBS for 10min and non-specific protein binding blocked by incubation with 10% normal rabbit serum (NRS) in PBS for 10min. Incubation with either affinity purified sheep anti N-myc (1:100 dilution of OA-1 1-803 in PBS/i % NRS) or the pan-myc antiserum OA-
N-myc specific sequence Figure 1 Sequence of the peptides used to generate the N-myc specific and pan-myc hetero-antisera. The N-myc, c-myc and Lmyc genes consist of three exons. Part of exon 2 and 3 are transcribed and translated to form the relevant myc protein. The sequence used to generate the pan-myc reagent was taken from a coding region in exon 2. The homology between the N-myc, cmyc and L-myc sequences is illustrated. The sequence used to generate the N-myc specific reagent was taken from a coding region in exon 3. The comparative c-myc, N-myc and L-myc sequences are illustrated, indicating the restricted nature of the N-myc sequence. c-myc sequence (Watt et al., 1983) ; N-myc sequence ; L-myc sequence (Ibson et al., 1987) .
11-801 (1:100 dilution of OA-11-801 in PBS/1% NRS) was performed overnight at 40C. Following three washes in PBS, the slides were incubated at room temperature for 1 h with biotin conjugated rabbit anti-sheep Ig (Vector BA 6000) diluted to 1:300 in PBS containing 1% NRS, 1% normal mouse serum and 1% normal human serum. The slides were washed a further three times in PBS and incubated for 30min with avidin/biotin/ peroxidase complex (Dako ABC reagent K355). After washing three times, the chromogen/substrate solution (0.5mgml-1 diaminobenzidine in PBS with 0.02% H202) was applied for 5-10min. The reaction was terminated by washing in PBS and slides mounted in Dako 'Glycergel'. Antiserum preincubated with a 100-fold molar excess of the immunising peptide was used as a negative control in all experiments.
Western blot analysis Tissues and cell lines in exponential growth phase were homogenised on ice in extraction buffer containing 10% glycerol, 0.1M Tris-HCl pH 6.8, 1mM EDTA, 2% SDS fimercaptoethanol, 1mM phenylmethylsulphonylfluoride and 20pgml-1 Leupeptin. The lysates were boiled for 3min and subsequently centrifuged for 15min at 10,000g. Supernatants were stored at -70°C for up to three weeks. The protein content of the supernatants was estimated by the method of Bradford (1976) . Aliquots (50pg) were loaded on to each lane of an 8% polyacrylamide gel (13cmx8cmxl.5mm) and electrophoresis carried out in the presence of SDS (Laemmli, 1970) at 20V for 16h. The gel was electroblotted on to 0.1 pm pore size nitrocellulose at I00V for 5 h at 15°C. Efficiency of transfer was assessed by Coomassie staining of the gel after blotting and by staining one lane of the nitrocellulose filter for total protein, by the Indian ink method of Hancock et al. (1983) .
Non-specific protein binding sites on the filter were blocked by incubation overnight in PBS/0.05% Tween 20 (Batteiger et al., 1982) . Incubation with OA-11-803 (sheep antibody to N-myc) or OA-11-801 (sheep antibody to panmyc) antisera diluted 1:200 in PBS/10% normal rabbit serum (or peptide absorbed control) was performed for 90 min at room temperature, followed by three washes, 5 min each, in PBS. The filter was subsequently incubated with either biotinylated or alkaline phosphatase conjugated rabbit anti-sheep Ig, diluted 1:2000 in PBS 10%/NRS for 1 h at RT. When the biotinylated second layer was used, this was followed by a 30 min incubation with Streptavidin conjugated alkaline phosphatase diluted 1:1000 (BRL, Blue Gene Reagent). Colour development was performed in the dark by incubating the strips for 5-30min in substrate solution. The chromogenic substrate was made up by adding 4.4p1 Nitroblue tetrazolium (NBT) (at 75mgml-1 in 70% dimethylformamide and 3.3 pl 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (at 50mg ml-1 in dimethylformamide) to 1 ml of 0.1 M Tris HCI buffer pH 9.5 containing 0.1 M NaCl and 50 mMMg C12.
Results
A total of 12 medulloblastoma cases were examined. Due to the limited amount of fresh tissue available, it was not possible to perform all investigations in each case.
Southern blot analysis Following DNA extraction from medulloblastoma tissue and EcoRI digestion, faint 2 kb bands were identified as hybridising to the N-myc probe in all samples analysed (n = 9). intense 2kb signal was obtained from DNA isolated from a stage IV neuroblastoma carrying a 50-fold amplification of the N-myc gene. Similar experiments using the c-myc probe pUCLYXh16 also revealed no amplification of the c-myc gene. EcoRl digests of DNA probed with pUCLYXhl6 revealed two bands of 10 and 6kb of comparable intensity to the signal obtained from human placental DNA (data not presented).
To control for loading errors on the gels, blots were washed and re-proved with the DNA probe L2.30. This binds to a 2.2kb EcoRl fragment present as a single copy per haploid genome. Bands of equal intensity were obtained in all tracks analysed.
N-myc gene expression
The relative level of the N-myc protein was determined by a combination of immunocytochemical and biochemical techniques. Immunocytochemistry, using the affinity purified anti N-myc specific antiserum (OA-1 1-803), revealed dense nuclear staining of the Kelly neuroblastoma cell line known to carry a 100-fold amplification and to overexpress the Nmyc gene. Within this population, there was considerable heterogenity in the staining observed from cell to cell. The N-myc gene product was selectively localised to the nucleus, as neither the cytoplasm or nucleoli appeared to bind the reagent (Figure 3a) . In contrast, no staining of the Kelly cell line was observed when the antiserum was premixed with a 100-fold molar excess of the immunising peptide (Figure 3b) .
The promyelocytic leukaemia cell line HL60 and the colorectal carcinoma cell line COLO 320 DM did not bind OA-1 1-803, illustrating that the antiserum does not cross react with the c-myc protein (Figure 3c ). In addition, no binding was observed using the GHI cell line that does not constitutively express either c-myc or N-myc (Figure 3d ).
Analysis of medulloblastoma tissue sections revealed nuclear staining in 6/10 samples screened (Figure 4 ). Four samples gave background staining similar to that seen on tissues such as lymphoma (n = 3) and tonsil (n =4) which is known not to express the N-myc gene. Binding of the antiserum in the six positive samples could be blocked by preincubation of the antiserum with an excess of synthetic peptide.
No staining of a bank of formalin-fixed and paraffinembedded medulloblastoma tissue was observed using either the pan-myc or N-myc specific antisera, indicating that the N-myc protein is either denatured or degraded during fixation.
Western blot analysis of the N-myc protein To confirm that antiserum OA-1 1-803 actually recognises the N-myc gene product, medulloblastoma biopsies were homogenised and subjected to Western blot analysis. Figure  5 illustrates a typical result along with controls undertaken to ensure specificity of binding. A 63-66 kD doublet was observed binding to the N-myc specific antiserum OA-l 1-803. This is the normal positions of the N-myc protein(s) as determined by polyacrylamide gel electrophoresis. In addition, a 58 kD band was observed ( Figure 5, lane A) , which is considered to be a putative breakdown product of the N-myc gene. The intensity of this band varied from sample to sample. All other bands observed on the gels were due to non-specific binding of the antiserum, as they could not be removed following pre-incubation of OA-1 1-803 with Figure 5,  lane B) . Only the 63-66 kD proteins could be identified when antibody binding was visualised using an alkaline phosphatase rabbit anti-sheep Ig conjugate. However, the signal obtained under these circumstances was weak and, therefore, an additional amplification step was used to enhance photographic recording.
The 63-66 kD bands were only observed in medulloblastoma cell extracts shown to contain the N-myc protein by immunocytochemical analysis. In addition, no 63-66 kD doublet was apparent in extracts of the GH1 T-cell line, not expressing either c-or N-myc ( Figure 5, lane C) . As a positive control for these studies, extracts of the neuroblastoma cell line Kelly were also analysed by Western blot. OA-1 1-803 specifically bound to the 63-66 kD N-myc doublet and also showed weak reactivity to the 58 kD protein ( Figure 5, track D) . Binding to these proteins was again abolished by prior incubation of the antiserum with an excess of synthetic peptide ( Figure 5, lanes D and E) .
Indirect evidence that the protein being detected in the medulloblastoma tissues was N-myc is provided by analysing cell extracts from cell lines (COLO 320.DM and HL60) constitutively expressing the c-myc protein. No bnding was observed with OA-1 1-803, although the pan-myc antibody OA-1 1-801 did bind to the 63-66 kDa c-myc doublet ( Figure  6 ).
Clinical correlates
Two of the patients in this study died from causes not directly related to their tumour and a third was lost to follow-up. Of the remaining nine cases, five had tumours in which the N-myc gene product was identified and four had tumours with no evidence of gene expression. These two groups were well matched for age, site of tumour and degree of tumour resection and yet all patients with no detectable N-myc gene expression remain alive and well 8-54 months from the completion of treatment (Table I ). In contrast, 3/5 patients with demonstrable constitutive N-myc protein levels have died 7-54 months from initial therapy. The other two remain disease-free 36 and 55 months from the end of treatment. While the patient group is too small to be certain of the significance of these observations, there is a trend towards better survival in the group of patients in which the N-myc gene product was absent.
Discussion
Medulloblastomas and neuroblastomas share many common biological, histological and immunological features (Rorke et al., 1986) . Both tumour types may exhibit karyotypic abnormalities known as double minute chromosomes (Cox et al., 1965) In spite of the lack of N-myc amplification in the medulloblastoma tissues studied, 50% of samples appeared to be expressing the N-myc gene by immunohistological and Western blot studies using the anti N-myc specific anti-serum OA-11-803. Control studies on lines known to express either c-myc or N-myc clearly demonstrated the specificity of this reagent, as it does not bind to either c-myc in HL60 or COLO 320.DM cell lines. Although these lines have been shown to express c-myc, this was confirmed through the use of the anti-pan-myc reagent OA-11-801. Medulloblastoma, therefore, appears biologically different to neuroblastoma, where N-myc overexpression has been linked with amplification of the gene.
The immunohistological studies presented here were confirmed by Western blot analysis. Only those tumours expressing N-myc by immunohistological criteria were found to contain the 63-66kD doublet characterised as the N-myc protein(s). This biochemical data agrees with the findings of other groups using both immunoblotting and immunoprecipitation techniques, but is anomalous in that the size of the N-myc protein predicted from its nucleic acid sequence is only 49 kD. The protein is known to be phosphorylated but this modification is insufficient to explain the discrepancy.
In addition to the 63-66 kD doublet, we frequently observed faint bands thought to represent N-myc degradation products. These bands varied in intensity from sample to sample. In view of the short half life of the N-myc protein (t112 approx. 30min, Ramsay et al., 1986) it is essential that tissues are frozen immediately in order to avoid false negative results from either Western blot or immunocytochemical studies. This makes accurate quantification of N-myc protein levels extremely difficult. The failure to detect the N-myc protein in conventional formalin-fixed, paraffin-embedded sections may be due to either denaturation or proteolysis, resulting from the relatively slow diffusion of fixative into tissue and/or the use of high melting point waxes. Initially, we had hoped that an immunological approach to identify the N-myc gene product would prove more reliable than studies of mRNA, but in this instance both protein and mRNA are highly labile. Seeger et al. (1985) have shown that N-myc amplification in neuroblastoma is correlated with relapse-free survival. The cause of this relationship remains speculative. This could be due to either the generation of cytogenetic abnormalities within the malignant cells (HSRs and DMs) or simply due to the overexpression of the N-myc gene. Although the number of cases presented here is small, a trend indicating that Nmyc expression is associated with a poorer prognosis is evident. If substantiated, this would support the contention that N-myc expression is the causal agent for the bad prognosis seen in this group of patients (and by inference, neuroblastoma patients) as none of the cases examined here had amplified N-myc genes. If the association between Nmyc expression and poor prognosis is supported by future studies, then N-myc expression might, like certain other histopathologic and clinical variables (Gilles et al., 1986) , become an important guide to both prognosis and therapy.
